{
  "catalysts": [
    {
      "ticker": "BOKF",
      "current_price": 128.21,
      "market_cap": "$8.15 Billion",
      "conviction_score": 9,
      "thesis": "BOK Financial reported a massive Q4 earnings beat on Jan 16 (EPS $2.89 vs $2.11 est, Revenue $589M vs $550M est), yet the stock only rose 0.4% on Friday. This muted reaction to a 33% EPS beat suggests significant mispricing and a strong PEAD setup for the coming week.",
      "catalyst_details": "Q4 Earnings Beat: EPS $2.89 (Beat by $0.78), Revenue $589.6M (Beat by ~$40M). Reported Jan 16, 2026.",
      "absorption_status": "Stock finished flat (+0.4%) despite a 'record' quarter and huge beat, indicating the news has not been absorbed or liquidity constraints dampened the initial move.",
      "earnings_date": "2026-04-20",
      "relative_volume": "1.1x (Normal)",
      "stop_loss_trigger": "$123.82 (1.5 ATR)",
      "sentiment": "Bullish",
      "prediction_market": "85% Bullish",
      "recency_proof": "https://investor.bokf.com/news/2026-01-16",
      "risk": "Regional banking sector headwinds",
      "expected_upside": "10-15% (Target $145) | Target: $136.99",
      "mispricing_evidence": "33% EPS beat with only 0.4% price move; P/E remains attractive at ~15x despite record profits.",
      "x_sentiment": "Quiet/Overlooked",
      "atr_value": 2.93,
      "calculated_stop_loss": 123.82,
      "calculated_target": 136.99
    },
    {
      "ticker": "ALMS",
      "current_price": 23.86,
      "market_cap": "$3.04 Billion",
      "conviction_score": 9,
      "thesis": "A Director purchased ~$10 million in stock (reported Jan 16/17), a massive vote of confidence following recent Phase 3 success. The stock closed down 1.2% on Friday, creating a divergence between price action and insider aggression.",
      "catalyst_details": "Insider Buying: Director Srinivas Akkaraju bought ~588k shares ($10M value) reported via Form 4 on Jan 16/17.",
      "absorption_status": "News of the filing broke late/over the weekend; Friday's price action (-1.2%) does not reflect this bullish signal.",
      "earnings_date": "2026-03-18",
      "relative_volume": "0.8x (Low on Friday)",
      "stop_loss_trigger": "$20.19 (1.5 ATR)",
      "sentiment": "Bullish",
      "prediction_market": "80% Bullish",
      "recency_proof": "https://www.sec.gov/Archives/edgar/data/1845938/000184593826000004/xslF345X03/wf-form4_1737060000.xml",
      "risk": "Biotech binary risk (though de-risked by recent data)",
      "expected_upside": "20%+ (Target $29) | Target: $31.20",
      "mispricing_evidence": "$10M insider buy at ~$17 levels confirms value; stock is consolidating recent gains but hasn't priced in the specific insider magnitude.",
      "x_sentiment": "Bullish",
      "atr_value": 2.45,
      "calculated_stop_loss": 20.19,
      "calculated_target": 31.2
    },
    {
      "ticker": "OCGN",
      "current_price": 1.69,
      "market_cap": "$506 Million",
      "conviction_score": 8,
      "thesis": "Ocugen released positive Phase 2 data for OCU410 in Geographic Atrophy (a multi-billion dollar market) on Jan 16, showing a 46% reduction in lesion growth. The stock only rose ~4%, likely due to historical skepticism, leaving the fundamental value of the data unpriced.",
      "catalyst_details": "Positive Phase 2 Data: OCU410 demonstrated 46% reduction in lesion growth in Geographic Atrophy patients. Moving to Phase 3.",
      "absorption_status": "Price rose only 4.3% on news that validates a major pipeline asset; market likely waiting for confirmation or digesting overhang.",
      "earnings_date": "2026-02-28",
      "relative_volume": "1.5x",
      "stop_loss_trigger": "$1.46 (1.5 ATR)",
      "sentiment": "Bullish",
      "prediction_market": "75% Bullish",
      "recency_proof": "https://ir.ocugen.com/news-releases/2026-01-16",
      "risk": "Dilution risk / Small cap volatility",
      "expected_upside": "30-50% (Target $2.50) | Target: $2.15",
      "mispricing_evidence": "Competitors in GA space have multi-billion valuations; OCGN market cap is ~$500M despite positive Phase 2 data.",
      "x_sentiment": "Rising Optimism",
      "atr_value": 0.15,
      "calculated_stop_loss": 1.46,
      "calculated_target": 2.15
    }
  ]
}